FDA Priority Review Accelerates Path for IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this…

Continue Reading FDA Priority Review Accelerates Path for IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia
STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG
qimono / Pixabay

STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG

Prednisone, oral steroids, intravenous hydrocortisone, and even blood transfusions are used to treat autoimmune hemolytic anemia (AIHA). AIHA comprises of warm AIHA, mixed AIHA, or cold agglutinin disease (CAD). Some…

Continue Reading STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG